Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 157 participants.

Also called NCT05475665

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 157 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05475665
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05475665. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-14 (actual); primary completion 2023-03-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
Condition
Essential Hypertension
Intervention (Drug)
Irbesartan/Amlodipine
Intervention (Drug)
Irbesartan
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct05475665
Content hash
3f16b85749952bffabdaecbb48421d9e5fbb7afe38685cf8fb6afe1f01d62fd0